BioCardia, Inc. (Nasdaq: BCDA) announced in a Form 8-K filed on September 10, 2026, that President and Chief Executive Officer Peter Altman, Ph.D., will present at the H.C. Wainwright 28th Annual Global Investment Conference.
The conference is scheduled to take place from September 14 to September 16, 2026, at the Lotte New York Palace Hotel in New York City. BioCardia’s presentation has been prerecorded and is expected to be available to conference participants beginning Friday, September 11, 2026. The company noted that it will not host a separate webcast.
The press release accompanying the filing details the company’s current regulatory and corporate progress. Regarding its CardiAMP autologous cell therapy, BioCardia stated it is preparing a Shonin pre-market regulatory submission to Japan’s Pharmaceutical and Medical Device Agency (PMDA) for approval of the therapy for ischemic heart failure. The company indicated this submission is targeted for the fourth quarter of 2026. Additionally, the company noted that FDA meeting minutes received in June confirmed that the ongoing randomized, double-blind CardiAMP HF II pivotal trial may support a Premarket Approval (PMA) for CardiAMP Cell Therapy in the United States.
The filing also highlights progress on the company’s Helix transendocardial delivery platform and Heart3D fusion imaging technology. BioCardia announced that it intends to submit a follow-on pre-submission for the Helix Transendocardial Delivery Catheter System during the third quarter of 2026. Furthermore, the company is advancing the Heart3D Fusion Imaging platform with its partner CART-Tech toward a potential FDA 510(k) submission.
